2020 SOA Virtual Health Meeting

KERRI MILLER, PHARMD, BLUEPRINT MEDICINES CORP.
IAN SMITH, FSA, MAAA, OPTUM ADVISORY SERVICES
GREGORY WARREN, FSA, MAAA, OPTUM ADVISORY SERVICES

Traditional Drug Development Process:
An Overview for Actuaries by Actuaries

June 9, 2020
Active participation in the Society of Actuaries is an important aspect of membership. While the positive contributions of professional societies and associations are well-recognized and encouraged, association activities are vulnerable to close antitrust scrutiny. By their very nature, associations bring together industry competitors and other market participants.

The United States antitrust laws aim to protect consumers by preserving the free economy and prohibiting anti-competitive business practices; they promote competition. There are both state and federal antitrust laws, although state antitrust laws closely follow federal law. The Sherman Act, is the primary U.S. antitrust law pertaining to association activities. The Sherman Act prohibits every contract, combination or conspiracy that places an unreasonable restraint on trade. There are, however, some activities that are illegal under all circumstances, such as price fixing, market allocation and collusive bidding.

There is no safe harbor under the antitrust law for professional association activities. Therefore, association meeting participants should refrain from discussing any activity that could potentially be construed as having an anti-competitive effect. Discussions relating to product or service pricing, market allocations, membership restrictions, product standardization or other conditions on trade could arguably be perceived as a restraint on trade and may expose the SOA and its members to antitrust enforcement procedures.

While participating in all SOA in person meetings, webinars, teleconferences or side discussions, you should avoid discussing competitively sensitive information with competitors and follow these guidelines:

- Do not discuss prices for services or products or anything else that might affect prices
- Do not discuss what you or other entities plan to do in a particular geographic or product markets or with particular customers.
- Do not speak on behalf of the SOA or any of its committees unless specifically authorized to do so.
- Do leave a meeting where any anticompetitive pricing or market allocation discussion occurs.
- Do alert SOA staff and/or legal counsel to any concerning discussions
- Do consult with legal counsel before raising any matter or making a statement that may involve competitively sensitive information.

Adherence to these guidelines involves not only avoidance of antitrust violations, but avoidance of behavior which might be so construed. These guidelines only provide an overview of prohibited activities. SOA legal counsel reviews meeting agenda and materials as deemed appropriate and any discussion that departs from the formal agenda should be scrutinized carefully. Antitrust compliance is everyone’s responsibility, however, please seek legal counsel if you have any questions or concerns.
Presentation Disclaimer

Presentations are intended for educational purposes only and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually and, unless expressly stated to the contrary, are not the opinion or position of the Society of Actuaries, its cosponsors or its committees. The Society of Actuaries does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented. Attendees should note that the sessions are audio-recorded and may be published in various media, including print, audio and video formats without further notice.
The United States spends roughly twice as much as comparable countries on a per capita basis—18 percent of gross domestic product (GDP) in the United States is spent on health care, compared to 11 percent of GDP in comparable countries.

The Society of Actuaries (SOA) joined forces with the Kaiser Family Foundation (KFF) in 2017 to charter Initiative 18|11: What Can We Do About the Cost of Health Care? The Healthcare Financing Management Association (HFMA) later joined the effort.
Introduction & Background

Initiative 18/11: Actuarial Perspectives on Prescription Drug Financing

The inaugural event for Initiative 18|11 occurred on March 7, 2018, in Washington, D.C.

- The meeting attendees included more than 30 thought leaders throughout the health care community, including actuaries, health economists, employee benefits experts and hospital administrators.

- Participants focused on two key drivers: the price of goods and services and the chronic disease burden.

- Participants also noted that fragmentation of care within the United States can result in unnecessary administrative expenses and make finding solutions more difficult.

- Several participants lamented the lack of transparency in the current health care system, especially in terms of how pharmacy prices are determined.

- With that in mind, the Initiative 18|11 leadership, along with the Health Section Council of the SOA, launched a strategic initiative entitled “Actuarial Perspectives on Prescription Drug Financing” to document and analyze the underlying process.
Actuarial Perspectives on Prescription Drug Financing: 4 Research Areas

1. **Drug Development Process** — what are the phases of the drug development process, what happens in each, how does it all end up in a new therapy on the market and what does it cost?

2. **Economic Impact** — how much is spent on prescription drugs in the United States, what are the various ways of measuring and reporting that, how is it changing over time and what is driving that change?

3. **Consumer Impact** — what is “direct-to-consumer” pharmaceutical advertising, what are manufacturer coupons and patient assistance programs, what are point-of-sale rebates and how do they all affect consumers in the United States?

4. **Regulatory Process** — what regulatory bodies exist at the state and federal level in the United States, what are their areas of oversight and what roles do they play in the pharmacy eco-system of the United States?
Actuarial Perspectives on Prescription Drug Financing: Series of Articles

“The Actuary” Web Exclusive Series entitled “Actuarial Perspectives on Prescription Drug Financing” was published in May 2020 with the following articles:

1. Traditional Drug Development Process (Drug Development Process)
2. Too Much or Too Little? (Economic Impact)
3. What is the Price Anyway? (Economic Impact)
4. Trends in Prescription Drug Spending (Economic Impact)
5. Direct-to-Consumer Pharmaceutical Advertising (Consumer Impact)
6. Manufacturer Coupons and Patient Assistance Programs (Consumer Impact)
7. Rebates at the Point of Sale (Consumer Impact)

Additional research is underway with anticipated articles on the following topics to be published later in 2020:

1. Specialty and Precision Medicine Development Process (Drug Development Process)
2. State and Federal Regulatory Oversight Process (Regulatory Process)
3. Additional Global Comparisons?? Other Topics??
Actuarial Perspectives on Prescription Drug Financing: Lessons Learned

**Introduction & Background**

Four areas actuaries can uniquely and positively contribute:

- Increasing transparency
- Encouraging competition
- Aligning stakeholder incentives
- Mitigating total cost of care increases

Traditional Drug Development Process: History of Medicines

1. Types of medicine:
   - Initially natural with mixed results
   - Now traditional medicines developed from nature with scientific approach

2. Ideas used to come from active ingredients of existing remedies or serendipitous discoveries

3. More recently drug discovery comes from more definitive laboratorial progression steps:
   - Identifying and validating a target
   - Generating assays to find lead compounds
   - Optimizing lead compounds to increase affinity and efficacy and reduce potential side effects

4. More complex discovery processes require more time and capital investment

5. Expanded skill sets now leveraged in drug discovery process:
   - chemists,
   - physiologists
   - statisticians
   - biochemists
   - Molecular biologists
   - toxicologists
   - pharmacologists
   - computer scientists leveraging data from chemical libraries and gene sequencing efforts
Traditional Drug Development Process: Funding Mechanisms

1. Historically, government and philanthropic organizations funded early basic discovery.
2. Pharmaceutical companies and venture capitalists funded drug discovery and late-stage development.
3. Increased costs have led to increased venture capital involvement.
4. Direct and/or indirect public funding (mainly through National Institutes of Health) still exists to some degree in at least the early stages for almost every drug that comes to market.
5. In 2016 over $150 Billion invested worldwide in drug research and development when public and private funding sources are combined.

Figure 1: Business and Government R&D Spending
Agenda

- Introduction & Background
- Research & Discovery
- Development & Approval
- Drug Development Costs
Audience Analysis - Polling Question

Q: How familiar are you with the drug development process?
   1. Not familiar at all
   2. Basic familiarity
   3. Working knowledge
   4. Extremely knowledgeable
Research & Discovery

- Target Identification and Validation
- Lead Compound Screening
- Lead Compound Optimization
Disease Target Identification & Validation

Protein (receptor) that performs a biological function

Drugs attack or modify the target protein that leads to disease

Target ideas

Artificial Intelligence

Academic research
Scientific literature
Bioinformatics data mining
Two top screening methods are high-throughput screening (HTS) and knowledge-based screening.

HTS uses automated robotics to quickly perform millions of assays to match the drug-like properties with libraries of compounds.

“he wanted to send all 12,000 compounds to Hong Kong, along with high-throughput screening equipment”
Lead Compound Optimization

Iterative rounds of synthesis

- How potent/selective to the target protein vs. non-target proteins
- Select the one that most actively binds to the target
Example: Protein Kinase “family tree”

- Regulate multiple biological processes
- Cancer often involves alterations in kinase activity
- Kinases represent important targets in drug design

https://doi.org/10.7717/peerj.126/fig-6
Lead Compound Optimization

Structure modifications

- properties to balance out intensity, specificity, toxicity, instability, etc.

<table>
<thead>
<tr>
<th>Pravastatin (acid) (R=b)</th>
<th>Simvastatin (lactone) (R=a)</th>
<th>Lovastatin (lactone) (R=a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pravastatin lactone (R=a)</td>
<td>Simvastatin acid (R=b)</td>
<td>Lovastatin acid (R=b)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fluvastatin (acid) (R=b)</th>
<th>Atorvastatin (acid) (R=c)</th>
<th>Cerivastatin (acid) (R=b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluvastatin lactone (R=a)</td>
<td>Atorvastatin lactone (R=a)</td>
<td>Cerivastatin lactone (R=a)</td>
</tr>
</tbody>
</table>
Agenda

- Introduction & Background
- Research & Discovery
- Development & Approval
- Drug Development Costs
Development and Approval

- Pre-clinical Studies
- IND Request with FDA
- Clinical trials
- NDA Filing with FDA
- Post-Market Safety Monitoring
Pre-Clinical Studies

• Preliminary efficacy, toxicity, pharmacokinetic and pharmacodynamic information

• Failure reasons: excessive toxicity

• In vitro testing

• In vivo testing
Investigational New Drug (IND) Request

Start of human clinical trails

All pre-clinical study info and data

Needed to ship experimental drug across state lines

20-year patent exclusivity begins upon IND approval.
Clinical Trials

**Phase 1**
Few dozen healthy volunteers – PK/PD
Max effective dose

**Phase 2**
100s of patients with disease of interest
Establish optimal dose

**Phase 3**
100s to 1000s of pts with disease
FDA defines endpoints to determine success/failure
Drug Denials - Polling Question

Q: Which is NOT a reason a drug might be denied approval by the FDA?

1. Too expensive
2. Safety concerns
3. Manufacturing issues
4. Lack of efficacy
New Drug Application (NDA)

Expedited review opportunities via 1992 Prescription Drug User Fee Act (PDUFA)

- Fast Track designation
- Accelerated Approval
- Priority Review
- Breakthrough Therapy designation

File after phase 2 or phase 3 results are promising.

Key Factors FDA considers:

<table>
<thead>
<tr>
<th>Data gathered during animal studies</th>
<th>Phase 1/2/3 study results</th>
<th>Drug abuse potential</th>
<th>Manuf. info</th>
<th>Proposed label indication and use</th>
</tr>
</thead>
</table>
FDA Post-Market Safety Monitoring

Key Goals:
Ensure continued effectiveness.
Inform consumers about side effects or problems.

Routine inspections of manufacturing facilities

Monitors
Drug advertisements
Promotional activity
Safety reports

Actions
Warning letters
Product seizure
Criminal prosecution/fines
Agenda

- Introduction & Background
- Research & Discovery
- Development & Approval
- Drug Development Costs
Topics for discussion

<table>
<thead>
<tr>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Development Costs and relationship to price</td>
</tr>
<tr>
<td>Drug Types and relationship to price</td>
</tr>
<tr>
<td>Other pricing considerations</td>
</tr>
<tr>
<td>Actuarial consideration of prices</td>
</tr>
</tbody>
</table>
Drug Development Costs and Relationship to Price

1. Costs of developing a new pharmaceutical vary drastically
   a) One study of cancer prescriptions estimated $1.4B per approved drug (DiMasi, et al 2013)
   b) Another estimated $760M (Prasad, et al 2017)
2. Other studies have focused on the treatment of more broad categories and have found that rare disease treatments can have $170M and non-orphan costs are around $290M
   a) The discrepancy seems to be largely around the cost of research and development and differing approval processes
3. In many industries the cost of development, materials, and labor would be enough to ascertain what these drugs should cost. However, in the United States there are other considerations…
Drug Development Costs and Relationship to Price

1. In the United States the free market is allowed to determine the cost of goods.
2. As such the price of drugs is largely determined by what the market will bare for a particular drug and has relatively little to do with the costs of bringing the particular drug to market.
3. What is used to determine what the market will bare is based on many factors:
   a) Type of drug being developed and its relationship to others already on the market.
   b) Type of drug being developed and its relationship of the new drug to others in its therapeutic class.
   c) Other drug pricing considerations.
## Drug Type: New Drug to Saturated Market

### Scenario
- Population is known
- Direct drug competitors already on the market

### Example
- Additional SGLT-2s to diabetes market

### Actuarial Methods
- Use historical experience to anticipate cost and frequency

### Pharmacy Could Provide…
- No big/changing events, so no need for external info

---

Current Utilizing Population

New Drug
**Drug Type:** New Method of Action (MOA) to Established Market

### Scenario
- Population is known
- *No direct drug competitors* on the market

### Actuarial Methods
- Estimate shift to new drug using similar scenarios for different drugs
- Estimate cost using published reports, expert opinion (i.e. Health Technology Pipeline)

### Example
- New oral product in RA

### Pharmacy Could Provide...
- Expected shift percent
- Expected costs

---

**Current Utilizing**
- New Utilizers
- Population

**New Drug**
Drug Type: New MOA to Unsatisfied Market

**Scenario**
- Population is *unknown*
- *No direct drug competitors* on the market

**Actuarial Methods**
- Similar to New MOA in established market
- Additionally, estimate “warehoused” population through historical diagnoses and online research

**Example**
- First Launches of New Hepatitis C

**Pharmacy Could Provide...**
- Expected shift percent & costs
- Estimate of disease in total insured population

![Diagram showing warehoused population, current utilizing population, and new drug]](image-url)
Other Pricing Considerations

Institute for Clinical and Economic Review (ICER) is a Boston-based institute that describes itself as “a trustworthy, independent source to help assess how valuable a new drug really is.”

ICER evaluates the clinical and economic value of prescription drugs, medical tests, and other health care and health care delivery innovations.

ICER produces drug assessment reports that provide an analysis of how well a drug works
- How much better is it than what we already have?
- How much could it save us?
- How much would it cost to treat everyone who needs it?

Reports give a price benchmark based on models used to determine long-term value-based approach to drug pricing.
Actuarial Pricing Considerations

1. Actuaries can generally make fairly good predictions on the prices of new drugs within the market when taking into consideration a new drug’s type, relationship to the existing market and relationship to other treatments in its therapeutic class.

2. However, consistently updating assumptions and looking back on methodology to compare to actuals is needed.
   a) For example, new Hepatitis C therapies in 2013.
Thank you.